Belgium· BE-AMP-SAM666461-00
Etcamah 75 mg
A camizestrant product containing camizestrant, registered in Belgium by AstraZeneca. The same ATC class is registered in 6 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Camizestrant is registered in 6 of 19 countries.
Countries holding a registration under ATC L02BA05 (camizestrant), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 4 of them publish a price we can compare per daily dose
Camizestrant · ATC L02BA05
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Camizestrant
- Manufacturer
- AstraZeneca
- Country
- Belgium (BE)
- ATC code
- L02BA05
- ATC class
- Camizestrant
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Camizestrant in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaETCAMAHAstraZeneca AB, Södertälje
- FinlandETCAMAHAstraZeneca AB
- PolandEtcamahAstraZeneca AB
- SwedenEtcamah 75 mg Filmdragerad tablettAstraZeneca AB
- United StatesETCAMAHAstraZeneca Pharmaceuticals LP
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Etcamah
- Liechtenstein · Etcamah
- Norway · Etcamah
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3e481b91-6ed6-4ded-9b56-b86ff30d0727 GET /v1/drugs/3e481b91-6ed6-4ded-9b56-b86ff30d0727?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Etcamah 75 mg",
"name_fr": "Etcamah 75 mg",
"name_nl": "Etcamah 75 mg",
"amp_code": "SAM666461-00",
"strengths": [
"75.0000"
],
"pack_count": 1,
"substances": [
"Camizestrant",
"Sodium Starch Glycolate (Type A)"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Camizestrant",
"authorisation_numbers": [
"EU/1/26/2046/001"
]
}See everything about camizestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.